248P Sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments

B Xu,T Luo,X Zeng,J Chen,T Sun,X Wu,W Li,X Wang,F Ma,X.J Cong,S Wang,Z Tong,Y Pan,W Zhao,J Yang,H Yao

doi:10.1016/j.annonc.2022.07.287

248P Sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments

B Xu, T Luo + Show 14 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.287

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
Citations: 1	License type: publisher-specific-oa

#Chinese Patients #Sacituzumab Govitecan + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Refractory or relapsing metastatic triple-negative breast cancer (mTNBC) has a poor prognosis. Sacituzumab govitecan (SG) is a novel antibody-drug conjugate, targeting human trophoblast cell-surface antigen 2. This is the first time to report the efficacy and safety of SG in Chinese mTNBC patients.

Full Text